Similarly, our results suggested that GBM patients with higher expression of Ki67 suffered remarkably worse OS and PFS than those with lower expression of Ki67, and except for the patients with lower Ki67 expression, extended TMZ chemotherapy also significantly benefited GBM patients with higher Ki67 expression with prolonged OS and PFS. This evidence concerns the gene MKI67 and glioblastoma.